John Stone, MD
Enriched profileDirector of Clinical Rheumatology, Massachusetts General Hospital; Edward A. Fox Chair in Medicine; Professor of Medicine, Harvard Medical School · Massachusetts General Hospital
John Stone is Director of Clinical Rheumatology, Massachusetts General Hospital; Edward A. Fox Chair in Medicine; Professor of Medicine, Harvard Medical School at Massachusetts General Hospital. ClinicalTrials.gov lists 8 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 17 Oct 2026
John Stone, M.D., is Director of Clinical Rheumatology, Massachusetts General Hospital. The public record shows 47 publications with 2,253 citations (h-index 15), centered on Immunoglobulin G4-Related Disease. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 22 companies, 2 NIH-funded awards (2011–2026).
- Top research focus: Immunoglobulin G4-Related Disease
- 8 registered trials on ClinicalTrials.gov
- Open Payments reporting from 22 companies
Generated from the cited public record · current as of 17 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- Advocates for reducing insurance/prior-authorization access barriers for patients with IgG4-related disease
in his capacity as Executive Chairman of the IgG4ward! Foundation
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hcplive.com ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 17 Oct 2026
Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:
- Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- Efficacy of Tocilizumab on Patients With COVID-19
Sponsor: Massachusetts General Hospital
- Safety and Efficacy of Abatacept in IgG4-Related Disease
Sponsor: Massachusetts General Hospital
Industry payments
Updated 17 Oct 2026
22 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year202524 payments$31,024openpaymentsdata.cms.gov ↗
- Merck Sharp & Dohme LLCProgram year20252 payments
- ARGENX US, INC.Program year20252 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
50%JAK inhibitor25%Xeljanz Xr100%Part D<11 patientsTNF inhibitor25%Humira Pen100%Part D<11 patientsMetabolism & gastrointestinal
32.4%Corticosteroid32.4%Prednisone100%Part D<11 patientsCardiovascular
17.6%Beta blocker17.6%Carvedilol100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 17 Oct 2026
2 NIH research awards on record, funded 2011–2026 per NIH RePORTER. The latest:
- Targeting T cell Subsets in Autoimmune Disease
Massachusetts General Hospital
FY2026$333,918UM1AI144295 - Targeting T cell Subsets in Autoimmune Disease
Massachusetts General Hospital
FY2025$333,918UM1AI144295 - Targeting T cell Subsets in Autoimmune Disease
Massachusetts General Hospital
FY2024$333,918UM1AI144295
Publications
None on file yet. We only list publications we can confidently match to this person. Why? →
Online presence
Updated 17 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- LinkedIn
linkedin.com/in/john-stone-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- Other
healio.com/news/rheumatology/podcasts/rheuminations/episode-twenty-one
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healio.com ↗ - X / Twitter
x.com/IgG4ward
- YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 17 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →advances.massgeneral.org ↗
- Board Certified
Internal Medicine, American Board of Internal Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗ - Board Certified
Rheumatology, American Board of Internal Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Editorial & leadership roles
journal and society appointments- Founder & Executive Chairman
The IgG4ward! Foundation
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →igg4ward.org ↗ - Editor
"A Clinician's Pearls and Myths in Rheumatology"
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →booksoup.com ↗ - Chair
Steritas Scientific Advisory Board
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →steritas.com ↗ - Co-director
Advances in Rheumatology course, Massachusetts General Hospital
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →advances.massgeneral.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hcplive.com ↗
- Podcast: "IgG4-related Disease with John Stone, MD"
Rheuminations series (Healio)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healio.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →emjreviews.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →rarerevolutionmagazine.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healio.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
James Januzzi, MD
Massachusetts General Hospital
Maurizio Fava, MD
Massachusetts General Hospital
Steven Greenberg, MD
Massachusetts General Hospital
David Scadden, MD
Massachusetts General Hospital
Marc Hochberg, MD
University of Maryland School of Medicine
Michelle Petri, MD
Johns Hopkins University School of Medicine
Dinesh Khanna, MD
University of Michigan
Matthew Liang, MD
Brigham and Women's Hospital